{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:15:45Z","timestamp":1785842145036,"version":"3.56.0"},"reference-count":43,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,6,15]]},"abstract":"<jats:p> PURPOSE: Few chemotherapy agents are active in leiomyosarcoma (LMS), particularly LMS that has progressed after doxorubicin treatment. We sought to determine the response to gemcitabine plus docetaxel among patients with LMS. <\/jats:p><jats:p> PATIENTS AND METHODS: Patients with unresectable LMS of uterine (n = 29) or other (n = 5) primary sites who did not respond to zero to two prior chemotherapy regimens were enrolled onto a phase II study of gemcitabine 900 mg\/m<jats:sup>2<\/jats:sup> intravenously (IV) on days 1 and 8 plus docetaxel 100 mg\/m<jats:sup>2<\/jats:sup> IV on day 8 with granulocyte colony-stimulating factor given subcutaneously on days 9 to 15, delivered every 21 days. Patients with prior pelvic radiation received 25% lower doses of both agents. Gemcitabine was delivered over 30 or 90 minutes in cycles 1 and 2 and by 90-minute infusion in all subsequent cycles. Pharmacokinetic studies assessed in vivo differences in gemcitabine concentrations with different rates of infusion. <\/jats:p><jats:p> RESULTS: Thirty-four patients (median age, 55 years; range, 32 to 74 years) have enrolled. Fourteen had received prior pelvic radiation. Sixteen of 34 patients had progressed after doxorubicin-based therapy; 18 had no prior chemotherapy. Among 34 patients, complete response was observed in three patients and partial response in 15, for an overall response rate of 53% (95% confidence interval, 35% to 70%). Seven patients had stable disease. Fifty percent of patients previously treated with doxorubicin responded. Hematologic toxicity was common (neutropenia: grade 3, 15%; grade 4, 6%; thrombocytopenia: grade 3, 26%; grade 4, 3%), but neutropenic fever (6%) and bleeding events (0%) were rare. The median time to progression was 5.6 months (range, 4 to 10 months). <\/jats:p><jats:p> CONCLUSION: Gemcitabine plus docetaxel is tolerable and highly active in treated and untreated patients with LMS. <\/jats:p>","DOI":"10.1200\/jco.2002.11.050","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T20:11:44Z","timestamp":1034367104000},"page":"2824-2831","source":"Crossref","is-referenced-by-count":571,"title":["Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial"],"prefix":"10.1200","volume":"20","author":[{"given":"Martee L.","family":"Hensley","sequence":"first","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Maki","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Venkatraman","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennifer","family":"Geller","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Lovegren","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sabbatini","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tong","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Barakat","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Spriggs","sequence":"additional","affiliation":[{"name":"From the Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-109704","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.2820710440"},{"key":"R2-109704","doi-asserted-by":"publisher","DOI":"10.3109\/02841869509127189"},{"key":"R3-109704","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(92)90286-R"},{"key":"R4-109704","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-000-0061-6"},{"key":"R5-109704","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.11.1962"},{"key":"R6-109704","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199002000-00009"},{"key":"R7-109704","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199804000-00010"},{"key":"R8-109704","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1998.5080"},{"key":"R9-109704","doi-asserted-by":"crossref","unstructured":"Slayton  R,   Blessing  J,   Look  K,  et al:   A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus:  A Gynecologic Oncology Group study.   Invest New Drugs 9:  207,1991-208,","DOI":"10.1007\/BF00175091"},{"key":"R10-109704","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6482"},{"key":"R11-109704","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(92)91671-V"},{"key":"R12-109704","unstructured":"Slayton  R,   Blessing  J,   Ange  C,  et al:   Phase II trial of etoposide in the management of advanced or recurrent leiomyosarcoma of the uterus:  A Gynecologic Oncology Group study.   Cancer Treat Rep 71:  1303,1987-1304,"},{"key":"R13-109704","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830815)52:4<626::AID-CNCR2820520409>3.0.CO;2-E"},{"key":"R14-109704","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1996.0091"},{"key":"R15-109704","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1996.0220"},{"key":"R16-109704","unstructured":"Heinemann  V,   Xu  YZ,   Chubb  S,  et al:   Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2\u20322\u2032-difluorodeoxycytidine.  Mol Pharmacol 38:  567,1990-572,"},{"key":"R17-109704","unstructured":"Huang  P,   Chubb  S,   Hertel  LW,  et al:   Action of 2\u20322\u2032-difluorodeoxycytidine on DNA synthesis.  Cancer Res 51:  6110,1991-6117,"},{"key":"R18-109704","doi-asserted-by":"crossref","unstructured":"Plunkett  W,   Huang  P,   Gandhi  V:   Preclinical characteristics of gemcitabine.  Anticancer Drugs 6:  7,1995-13,     (suppl 6)","DOI":"10.1097\/00001813-199512006-00002"},{"key":"R19-109704","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.749"},{"key":"R20-109704","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.4.288"},{"key":"R21-109704","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2879"},{"key":"R22-109704","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.12.2886"},{"key":"R23-109704","unstructured":"Plunkett  W,   Puang  P,   Searcy  CE,  et al:   Gemcitabine:  Preclinical pharmacology and mechanisms of action.   Semin Oncol 23:  3,1996-15,     (suppl 10)"},{"key":"R24-109704","doi-asserted-by":"crossref","unstructured":"Abbruzzese  JL,   Grunewald  R,   Weeks  EA,  et al:   A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.  J Clin Oncol 10:  406,1991-413,","DOI":"10.1200\/JCO.1992.10.3.406"},{"key":"R25-109704","unstructured":"Grunewald  R,   Kantarjian  H,   Keating  MJ,  et al:   Pharmacologically directed design of the dose rate and schedule of 2\u20322\u2032-difluorodeoxycytidine (gemcitabine) administration in leukemia.  Cancer Res 50:  6823,1990-6826,"},{"key":"R26-109704","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685109"},{"key":"R27-109704","doi-asserted-by":"crossref","unstructured":"Abbruzzese  JL,   Grunewald  R,   Weeks  EA,  et al:   A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.  J Clin Oncol 10:  406,1991-413,","DOI":"10.1200\/JCO.1992.10.3.406"},{"key":"R28-109704","unstructured":"Huang  P,   Chubb  S,   Hertel  LW,  et al:   Action of 2\u20322\u2032-difluorodeoxcytidine on DNA synthesis.  Cancer Res 51:  6110,1991-6117,"},{"key":"R30-109704","unstructured":"Cozzi  PJ,   Bajorin  DF,   Tong  W,  et al:   Toxicology and pharmacokinetics of intravesical gemcitabine:  A preclinical study in dogs.   Clin Cancer Res 5:  2629,1999-2637,"},{"key":"R31-109704","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(94)00521-6"},{"key":"R33-109704","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"R35-109704","unstructured":"Van Glabbeke  MM,   Hogendoorn  PCW,   Mouridsen  H,  et al:   Progression free rate as the principal end-point for phase II trial on soft tissue sarcoma:  What should be the target? A retrospective study of the EORTC soft tissue and bone sarcoma (STBSG) database.   Proc Am Soc Clin Oncol 20:  354a,2001  (abstr 1413)"},{"key":"R36-109704","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058909"},{"key":"R37-109704","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.10.2081"},{"key":"R38-109704","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.15.3483"},{"key":"R39-109704","unstructured":"Tempero  M,   Plunkett  W,   van Haperen  VR,  et al:   Randomized phase II trial of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic adenocarcinoma.  Proc Am Soc Clin Oncol 18:  273a,1999  (abstr 1048)"},{"key":"R40-109704","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.914"},{"key":"R41-109704","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.9.1821"},{"key":"R42-109704","doi-asserted-by":"crossref","unstructured":"Gatzmeier  U,   Shepherd  FA,   Le Chevalier  T,  et al:   Activity of gemcitabine in patients with non\u2013small cell lung cancer:  A multicentre extended phase II study.   Eur J Cancer 32A:  243,1996-248,","DOI":"10.1016\/0959-8049(95)00444-0"},{"key":"R43-109704","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.311"},{"key":"R44-109704","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1232"},{"key":"R45-109704","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1649"},{"key":"R46-109704","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3866"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.11.050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:51:48Z","timestamp":1653515508000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.11.050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6,15]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2002,6,15]]}},"alternative-id":["10.1200\/JCO.2002.11.050"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.11.050","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6,15]]}}}